← Back to home

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED)

Clinical trials for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED) explained in plain language.

Never miss a new study

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED) trials appear

Sign up with your email to follow new studies for AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for hair regrowth in rare immune disorder

Disease control Recruiting now

This study is testing if the drug ruxolitinib can help regrow hair in people with a rare immune system disorder called APECED who have severe hair loss (alopecia areata). About 70 participants, aged 12 to 65, will take the drug as a pill twice a day for 8 months. Researchers will…

Matched conditions: AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED)

Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED)

Get alerted when new AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED) trials appear

New hope for hair regrowth in rare immune disorder